Long-term follow-up after switching from originator infliximab to its biosimilar CT-P13: the weight of nocebo effect

Ann Rheum Dis. 2020 Jan;79(1):e11. doi: 10.1136/annrheumdis-2018-214374. Epub 2018 Oct 23.

Authors

Vincent Germain^#^{1

2}, Marc Scherlinger^#^{1

2

3}, Thomas Barnetche¹, Thierry Schaeverbeke^{4

2}; Fédération Hospitalo-universitaire ACRONIM

Affiliations

¹ Department of Rheumatology, Centre Hospitalier Universitaire de Bordeaux, Service de Rhumatologie, Bordeaux, France.
² Department of Rheumatology, Université de Bordeaux, Bordeaux, France.
³ Department of Rheumatology, CNRS-UMR 5164 Immuno ConcEpT, Bordeaux, France.
⁴ Department of Rheumatology, Centre Hospitalier Universitaire de Bordeaux, Service de Rhumatologie, Bordeaux, France thierry.schaeverbeke@chu-bordeaux.fr.

^# Contributed equally.

PMID: 30352888
DOI: 10.1136/annrheumdis-2018-214374

No abstract available

Keywords: DMARDs (biologic); anti-TNF-alpha; nocebo effect; patient attitude to health; rheumatoid arthritis; spondyloarthritis.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Antirheumatic Agents / therapeutic use*
Biosimilar Pharmaceuticals
Drug Substitution*
Humans
Infliximab / therapeutic use*
Longitudinal Studies
Nocebo Effect*
Spondylitis, Ankylosing / drug therapy*

Substances

Antibodies, Monoclonal
Antirheumatic Agents
Biosimilar Pharmaceuticals
CT-P13
Infliximab